Meeting
2023 ASCO Genitourinary Cancers Symposium
Characterization and survival benefit of drugs approved for advanced renal cell carcinoma.
Authors
David Joseph Benjamin
Hoag Family Cancer Institute, Newport Beach, CA
David Joseph Benjamin , Arash Rezazadeh
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral and Testicular Cancers
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 633)
DOI
10.1200/JCO.2023.41.6_suppl.633
Abstract #
633
Poster Bd #
F3
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Outcomes of immunotherapy (ICI) alone vs tyrosine kinase inhibitors (TKI) alone versus ICI and TKI combined in renal cell carcinoma brain metastasis.
First Author: Patrick Joseph O'Shea
Poster
2024 ASCO Genitourinary Cancers Symposium
Real-world metastatic renal cell carcinoma (mRCC) treatment trends in Mexico: A public vs private sector analysis.
First Author: Iván Romarico González Espinoza
Poster
2023 ASCO Genitourinary Cancers Symposium
Financial toxicity from first-line TKI plus IO therapies for advanced renal cell carcinoma.
First Author: David Joseph Benjamin
Poster
2023 ASCO Genitourinary Cancers Symposium
Estimated cost of adverse event (AE) management for patients (pts) with metastatic renal cell carcinoma (mRCC) treated with a VEGFR TKI.
First Author: Jeffrey Thomas Yorio